Status: current, Not sufficiently defined by necessary conditions definition status (core metadata concept). Date: 31-Oct 2016. Module: Canada Health Infoway English module (core metadata concept)
Descriptions:
Id | Description | Lang | Type | Status | Case? | Module |
138221000087117 | ProHIBiT 23 micrograms per 0.5 milliliter solution for injection Aventis Pasteur Inc. (real clinical drug) | en | Fully specified name | Active | Entire term case sensitive (core metadata concept) | Canada Health Infoway English module (core metadata concept) |
71661000087112 | Hib ProHIBiT AP | en | Synonym (core metadata concept) | Active | Entire term case sensitive (core metadata concept) | Canada Health Infoway English module (core metadata concept) |
71681000087118 | ProHIBiT 23 micrograms per 0.5 milliliter solution for injection Aventis Pasteur Inc. | en | Synonym (core metadata concept) | Active | Entire term case sensitive (core metadata concept) | Canada Health Infoway English module (core metadata concept) |
Outbound Relationships | Type | Target | Active | Characteristic | Refinability | Group | Values |
ProHIBiT 23 micrograms per 0.5 milliliter solution for injection Aventis Pasteur Inc. (real clinical drug) | est un(e) (attribut) | Product manufactured as parenteral dose form (product) | true | Inferred relationship | Some | ||
ProHIBiT 23 micrograms per 0.5 milliliter solution for injection Aventis Pasteur Inc. (real clinical drug) | a une forme pharmaceutique (attribut) | forme pharmaceutique pour usage parentéral (forme pharmaceutique) | true | Inferred relationship | Some | ||
ProHIBiT 23 micrograms per 0.5 milliliter solution for injection Aventis Pasteur Inc. (real clinical drug) | a pour principe actif (attribut) | Antigen of Haemophilus influenzae type b capsular polysaccharide polyribosylribitol phosphate conjugated to Corynebacterium diphtheriae toxoid protein (substance) | true | Inferred relationship | Some | 1 | |
ProHIBiT 23 micrograms per 0.5 milliliter solution for injection Aventis Pasteur Inc. (real clinical drug) | Plays role | Active immunity stimulant role (role) | true | Inferred relationship | Some | ||
ProHIBiT 23 micrograms per 0.5 milliliter solution for injection Aventis Pasteur Inc. (real clinical drug) | est un(e) (attribut) | Haemophilus influenzae type b capsular polysaccharide antigen conjugated only vaccine product | true | Inferred relationship | Some | ||
ProHIBiT 23 micrograms per 0.5 milliliter solution for injection Aventis Pasteur Inc. (real clinical drug) | Has supplier | Aventis Pasteur Inc. (supplier) | true | Inferred relationship | Some | ||
ProHIBiT 23 micrograms per 0.5 milliliter solution for injection Aventis Pasteur Inc. (real clinical drug) | Count of base of active ingredient | un | false | Inferred relationship | Some | ||
ProHIBiT 23 micrograms per 0.5 milliliter solution for injection Aventis Pasteur Inc. (real clinical drug) | a pour principe actif (attribut) | Haemophilus influenzae type b vaccine (substance) | false | Inferred relationship | Some | 1 | |
ProHIBiT 23 micrograms per 0.5 milliliter solution for injection Aventis Pasteur Inc. (real clinical drug) | est un(e) (attribut) | Haemophilus influenzae Type b vaccine | false | Inferred relationship | Some |
Inbound Relationships | Type | Active | Source | Characteristic | Refinability | Group |
This concept is not in any reference sets